CONVENE

Vice- Chair, Cheryl Adams called the meeting to order at 11:42 am.

Commission Members:
Elizabeth Jensen, PharmD
Tim Lynch, PharmD, Chair
Cheryl Adams, PharmD, Vice-Chair
Kat Wolf-Khachatourian, PharmD
Steve Anderson, RPh
Jerrie Allard, Public Member
Uyen Thorstensen, Pharmacy Technician
Kenneth Kenyon, PharmD, BCPS
Sepi Soleimanpour, RPh, MBA-HA
Matthew Ronayne, RPh
Teri Ferreira, RPh
Olgy Diaz, Public Member

Absent Commission Member:
Arun Sambataro, Public Member
Judy Guenther, Public Member
Michael Sieg, PharmD

Staff:
Eric Sonju, AAG
Steve Saxe, Executive Director
Tracy West, Deputy Director
Doreen Beebe, Program Manager
Leann George, Secretary Senior
Angelica Pauley, Pharmacist Consultant
Irina Tiginianu, Pharmacy Technician
Analyst

Call to Order
Business Meeting Agenda

MOTION: Elizabeth Jensen moved that the Commission approve the draft business meeting agenda with changes. Items 2.1 and 4.1 are information only. Ken Kenyon seconded. MOTION CARRIED: 10-0.
Old Business

Letter to the Legislative Health Care Committees
Executive Director, Steve Saxe updated the Commissioners on the status of the letter Commissioners tasked staff to draft to the Health Care Committees regarding drug compounding. Mr. Saxe provided an update which included staff working with both the DOH and the Governor’s policy staff on both process and strategy for moving the letter forward. This will be brought to the Commission in July as staff continues to work with both policy teams.

3.1 Hospital Pharmacy Associated Clinics (HPAC) Emergency Rule
Deputy Director, Tracy West asked the Commission to reauthorize emergency rule for Hospital Pharmacy Associated Clinics (HPAC), Chapter 246-873A to prevent a lapse in coverage. Staff hasn’t had an opportunity to meet with the sub-committee to do further work. It was previously discussed that the definition of compounding would need to be changed in this chapter to reflect the definition in statute that change was not made to the draft presented.

MOTION: Ken Kenyon moved that the Commission accept Chapter 246-873A as written and reauthorize refiling of CR 103e to prevent a lapse of coverage the seventh emergency rule will be effective for 120 days. Matthew Ronayne seconded. MOTION CARRIED: 10-0.

3.2 Schedule I Controlled Substances Emergency Rule
Deputy Director, Tracy West asked the Commission to reauthorize the emergency rule for Schedule I Controlled Substances that is currently filed as WSR 18-09-019. This is to prevent a lapse in coverage until the permanent rules are adopted. They will be filed within the next two months and this should be the last request for reauthorization.

MOTION: Steve Anderson moved that the Commission reauthorize the emergency rule for Schedule I Controlled Substances that is currently filed as WSR 18-09-019. Ken Kenyon seconded. MOTION CARRIED: 10-0.

*Tim Lynch arrived

Vice-Chair, Cheryl Adams respectfully passed the gavel to Chair, Tim Lynch to continue the meeting.

4.1 Formal Opinion Request from Medical Commission
The Medical Quality Assurance Commission has submitted a request for a formal opinion from the Attorney General’s Office regarding collaborative drug therapy agreements.
AAG, Eric Sonju, spoke to the procedures for this request. He made it clear that it would be best to submit the comments by the end of July. AAG, Christopher Gerard will be available to provide assistance.

Deputy Director, Tracy West and Executive Director, Steve Saxe have worked with AAG, Christopher Gerard on what would be the best approach for the commission to submit comments. Ms. West discussed two options, (1) would be to have a sub-committee work with Mr. Gerard on comments, or (2) a special meeting could be scheduled for the full Commission to engage is a larger discussion on comments. Regardless of the chosen direction the Commission decides, Mr. Gerard is available for the Commissioners. He will craft a document of proposed comments for the Commission to review at the July 26, 2018 Commission meeting.

There was a dialogue with the Commissioners, stakeholders and staff about the history of CDTA’s. There was discussion around pharmacist diagnosing and what that really means. During the discussion Chair, Tim Lynch introduced Melanie de Leon, Executive Director for the Medical Quality Assurance Commission. She was asked about the request and whether was she able to provide some understanding of the Medical Commissions concerns or issues. Ms. De Leon shared the MQAC does not have rules for their licensees on parameters for CDTAs. Ms. De Leon expressed that the MQAC wanted guidance and clarification on what should be delegated in a CDTA before the MQAC engages in any rulemaking.

The Commission chose to have a special meeting in person before the July business meeting to discuss and create comments to be submitted to the AGO. The Commission will come together in person and work on comments from the Commission as a whole. Other stakeholders are able to provide comments through the Attorney Generals website. Staff discussed sending this link out to stakeholders so individuals were able to provide their comments as well. The Commission encouraged stakeholders to share submitted comments with the Commission.

There being no further business, the board adjourned at 1:07 p.m.

Respectfully Submitted by:
Leann George, Program Support for Approval July 26, 2018

Tim Lynch, Chair
Washington State Pharmacy Quality Assurance Commission